Publication: Mass spectrometry based approaches for monoclonal antibody characterization and target discovery in endoplasmic reticulum associated protein degradation (ERAD) pathway
Loading...
Files
Date
Authors
Advisor
Journal Title
Journal ISSN
Volume Title
Publisher
ITU Graduate School
Type
Abstract
This thesis presents a comprehensive investigation into the application of advanced mass spectrometry-based approaches to address two critical challenges in modern biotechnology and cellular biology: the characterization of therapeutic monoclonal antibodies and the identification of novel protein targets within the endoplasmic reticulum-associated degradation (ERAD) pathway. Through the integration of sophisticated analytical techniques with cellular biology approaches, this research advances our understanding of both biopharmaceutical development and fundamental cellular protein quality control mechanisms. The research is structured around two complementary objectives that together demonstrate the versatility and power of mass spectrometry in biological research. The first objective focuses on establishing high-resolution analytical methodologies for the structural and functional profiling of monoclonal antibody Fab fragments, with particular emphasis on biosimilar characterization. The second objective employs proximity-dependent biotinylation techniques coupled with proteomic analysis to elucidate the interaction landscape of ERAD components, leading to the discovery of novel substrates and regulatory mechanisms in cellular protein homeostasis. The first major component of this research addresses the critical need for robust analytical frameworks in therapeutic antibody development, specifically focusing on ranibizumab, a humanized monoclonal antibody fragment targeting vascular endothelial growth factor A (VEGF-A). This therapeutic represents a sophisticated example of protein engineering that has revolutionized retinal disease treatment by transforming therapeutic goals from vision stabilization to actual visual improvement through precise molecular intervention in pathological angiogenesis. The characterization employed a multi-tiered mass spectrometry platform comprising four complementary analytical techniques: intact molecular weight determination under denaturing conditions, liquid chromatography-mass spectrometry profiling of reduced antibody subunits, deconvoluted mass analysis of individual heavy and light chains, and ion mobility-mass spectrometry for three-dimensional structural characterization. This comprehensive approach was designed to establish biosimilarity between reference and biosimilar antibody products across multiple structural levels. The analytical results demonstrated remarkable concordance between biosimilar and reference antibodies across all measured parameters. Intact mass spectrometry revealed virtually superimposable charge state envelope patterns and molecular weight distributions, indicating preservation of overall molecular architecture. Mass-to-charge ratio alignment across multiple charge states confirmed equivalent intact molecular composition, establishing biosimilarity at the global structural level. Reversed-phase liquid chromatography-mass spectrometry analysis of chemically reduced antibody chains revealed consistent chromatographic properties between both products. Light chain and heavy chain components showed identical elution patterns and retention times for both samples, confirming equivalent hydrophobic characteristics and chromatographic behavior of individual polypeptide subunits. Mass spectral deconvolution provided quantitative validation of subunit equivalence, with heavy chain and light chain masses showing identical values for both the biosimilar and reference products. Ion mobility-mass spectrometry enabled evaluation of higher-order structural preservation through gas-phase conformational analysis. Charge-state resolved drift time measurements and mass-selected mobility profiles yielded identical arrival time distributions between biosimilar and reference samples. Drift time consistency across charge states and analytical replicates indicated equivalent three-dimensional folding patterns, confirming that biosimilar production did not introduce conformational perturbations or structural destabilization. The second major research component employed proximity-dependent biotinylation (BioID2) coupled with mass spectrometry to systematically map interaction networks within the ERAD system. This approach was designed to overcome the limitations of traditional co-immunoprecipitation methods, which fail to capture the transient interactions characteristic of ERAD substrate processing due to the dynamic nature of binding and release during protein degradation. A sophisticated triple-point BioID2 system was developed targeting key ERAD machinery components: full-length Derlin-1 with C-terminal biotin ligase, truncated Derlin-1(1-170) that relocates the ligase to the ER lumen, and p97/VCP with both N- and C-terminal biotin ligase fusions. This strategic positioning enabled comprehensive coverage of ERAD process stages, capturing proteins interacting from both sides of the ER membrane and in cytosolic compartments where substrate extraction and processing occur. Venn diagram analysis revealed 12 proteins consistently biotinylated across all three constructs, with an additional 47 proteins shared between full-length and truncated Derlin-1 constructs, indicating both a conserved ERAD interaction core and domain-specific associations. Protein-protein interaction network analysis demonstrated dense connections among shared interactors, including canonical ERAD components as well as mitochondrial and nuclear-associated proteins. The most significant discovery was the identification of Prohibitin-2 (PHB2) as a novel, non-canonical ERAD substrate. PHB2, traditionally associated with mitochondrial inner membranes, appeared consistently across all three BioID2 constructs, suggesting genuine substrate-machinery relationships rather than coincidental interactions. This finding challenges conventional ERAD models that focus primarily on proteins synthesized and misfolded within the ER environment. Functional validation through cycloheximide chase assays demonstrated rapid, time-dependent PHB2 degradation in MCF-7 cells, with protein levels declining to less than 25% within 6 hours of protein synthesis inhibition. Immunoprecipitation studies following proteasome inhibition revealed time-dependent accumulation of high molecular weight ubiquitin-conjugated PHB2 species, confirming ubiquitin-mediated targeting consistent with ERAD substrate behavior. However, PHB2 degradation was only partially stabilized by proteasome inhibitor (MG132) or p97/VCP inhibitor (CB5083) treatment, indicating that additional degradation pathways—potentially lysosomal or autophagic mechanisms—may also contribute to its turnover. This incomplete stabilization distinguishes PHB2 from classical ERAD substrates and suggests substrate-specific routing within the broader cellular protein quality control landscape. Perhaps the most intriguing aspect of the PHB2 findings was the apparent connection to the ER-SURF (ER-to-mitochondria protein transfer) pathway. Live-cell imaging of GFP-tagged PHB2 revealed time-dependent increases in mitochondrial colocalization following protein synthesis inhibition, suggesting active relocalization rather than passive redistribution. This dynamic redistribution pattern is consistent with the ER-SURF pathway, a mechanism by which mitochondrial precursor proteins are initially targeted to the ER surface before transfer to mitochondria via specialized contact sites. The data suggest that the ER-SURF pathway may serve dual functions: not only delivering mitochondrial precursor proteins from their synthesis site to final destination, but also functioning as a quality control mechanism that routes damaged or surplus PHB2 from mitochondria back to the ER for ERAD-mediated degradation. This bidirectional traffic would represent a sophisticated inter-organelle communication system coordinating protein homeostasis across multiple cellular compartments. Immunocytochemistry analysis demonstrated robust colocalization between PHB2 and BioID2-tagged ERAD components (Derlin-1, truncated Derlin-1, and p97/VCP) in MCF-7 cells, with the strongest signal observed with the truncated Derlin-1 construct targeting the ER lumenal face. This finding suggests that PHB2 engages the ERAD system from the luminal or membrane-embedded side, possibly through the ERAD-L branch despite its primary mitochondrial association. The research revealed striking cell-type specificity in PHB2 degradation patterns that provides important insights into disease mechanisms. While PHB2 underwent efficient degradation in estrogen receptor-positive cell lines (MCF-7, BT-474) and non-tumorigenic mammary epithelial cells (MCF-12A), it remained remarkably stable in triple-negative MDA-MB-231 breast cancer cells. This differential regulation suggests that PHB2 turnover may be controlled by hormonal signaling or specific ERAD machinery components that are altered during malignant transformation. The resistance of PHB2 to degradation in MDA-MB-231 cells may reflect broader alterations in protein quality control systems that occur during cancer development. Triple-negative breast cancers are characterized by aggressive growth patterns, metabolic reprogramming, and altered cellular stress responses. The stabilization of PHB2 in these cells could contribute to altered mitochondrial function and energy metabolism, potentially supporting the aggressive phenotype of these tumors while offering new therapeutic vulnerabilities. The convergence of these two research components demonstrates the power of mass spectrometry-based approaches in addressing both practical therapeutic development needs and fundamental biological questions. The monoclonal antibody characterization work provides a robust analytical framework for biosimilar development and regulatory evaluation, while the ERAD pathway investigation reveals new complexity in cellular protein quality control systems. The identification of PHB2 as a non-canonical ERAD substrate expands our understanding of cellular protein quality control beyond traditional ER-resident proteins. This discovery suggests that ERAD functions as a broader cellular regulatory mechanism, coordinating protein homeostasis across multiple organelles through sophisticated inter-organelle communication systems. The cell-type specific regulation observed has important implications for understanding how cancer cells evade normal protein quality control systems.
Description
Thesis (Ph.D.) -- Istanbul Technical University, Graduate School, 2025
Journal or Series
ISSN
ISBN
Rights
Keywords
biyokimya, biochemistry, biyoteknoloji, biotechnology, antikorlar-monoklonal, antibodies-monoclonal, hücresel yolaklar, cellular pathways
Citation
Endorsement
Review
Supplemented By
Referenced By
Google Scholar
Scholar'da Ara ↗ Bu yayında DOI yok — Altmetric/Dimensions/PlumX/BIP! rozetleri DOI gerektirir.